- Home
- MDXH vs KRRO Comparison
MDXH vs KRRO Comparison
Compare MDXH & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- KRRO
- Stock Information
- Founded
- MDXH 2003
- KRRO 2014
- Country
- MDXH Belgium
- KRRO United States
- Employees
- MDXH N/A
- KRRO N/A
- Industry
- MDXH
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- KRRO Health Care
- Exchange
- MDXH Nasdaq
- KRRO Nasdaq
- Market Cap
- MDXH 141.1M
- KRRO 147.4M
- IPO Year
- MDXH 2021
- KRRO 2019
- Fundamental
- Price
- MDXH $3.55
- KRRO $23.08
- Analyst Decision
- MDXH Buy
- KRRO Strong Buy
- Analyst Count
- MDXH 1
- KRRO 7
- Target Price
- MDXH $6.00
- KRRO $96.71
- AVG Volume (30 Days)
- MDXH 172.3K
- KRRO 139.4K
- Earning Date
- MDXH 08-05-2025
- KRRO 08-12-2025
- Dividend Yield
- MDXH N/A
- KRRO N/A
- EPS Growth
- MDXH N/A
- KRRO N/A
- EPS
- MDXH N/A
- KRRO N/A
- Revenue
- MDXH $98,953,000.00
- KRRO $6,281,000.00
- Revenue This Year
- MDXH $24.77
- KRRO $97.27
- Revenue Next Year
- MDXH $22.21
- KRRO N/A
- P/E Ratio
- MDXH N/A
- KRRO N/A
- Revenue Growth
- MDXH 22.56
- KRRO N/A
- 52 Week Low
- MDXH $1.35
- KRRO $10.29
- 52 Week High
- MDXH $3.81
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- MDXH 73.83
- KRRO 71.54
- Support Level
- MDXH $2.86
- KRRO $19.54
- Resistance Level
- MDXH $3.81
- KRRO $21.63
- Average True Range (ATR)
- MDXH 0.22
- KRRO 1.97
- MACD
- MDXH 0.05
- KRRO 0.36
- Stochastic Oscillator
- MDXH 78.15
- KRRO 84.70
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.